Solara Active Pharma Sciences Limited — Important, 21-10-2024: Financial Result Updates

Solara Active Pharma Sciences reported its Q2 FY25 results, with revenue at INR 3,472 million, down 5% QoQ but showing strong gross margins of 50.5%, improved by 620 bps YoY. EBITDA rose 46% QoQ to INR 616 million, reflecting a margin of 17.7%. The company continued to reduce gross debt, and remains on track for projected FY25 revenue of ~INR 15,000 million, while emphasizing stable profitability and a stronger balance sheet.